Proposal of Common Data Elements for the European Platform of rare disease...

Similar documents
1. General Information About The Mitochondrial Disease Biobank

The NeurOmics team at a recent project meeting

How does a kidney transplant differ from dialysis?

What Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives

GENETICS AND GENOMICS IN NURSING PRACTICE SURVEY

Genetic Testing in Research & Healthcare

Act of 5 December 2003 No. 100 relating to the application of biotechnology in human medicine, etc

GROUP TOTAL & PERMANENT DISABILITY CLAIM FORM

Wilson Disease Research and Care. Looking Forward Ann Arbor, Michigan September 6, 2014 Fred Askari MD, PhD

Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases

Clinicians and patients needs and expectations from registries

If you are signing for a minor child, you refers to your child throughout the consent document.

PROVIDER POLICIES & PROCEDURES

Helping you find the one match.. Guide for Unrelated Stem Cell Transplant Patients OneMatch Stem Cell and Marrow Network BLOOD.

How To Find Out What People Think About Bioethics In Japanese University

FLORIDA MEDICAL CLINIC, P.A. NOTICE OF PRIVACY PRACTICES

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA

Short Term Disability Income Benefit. Employee s Guide

10/31/2014. Much is unknown. What is npod? THE JDRF Network for the Pancreatic Organ Donor with Diabetes (npod):

Usher Syndrome Genetics

NORD Guides for Physicians #1. Physician s Guide to. Tyrosinemia. Type 1

MODEL FORM. [Program s SART Name and Number] INFORMED CONSENT FOR EGG DONORS

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for

Cancer Patients Urgently Need Effective, Genetically-Targeted Treatments

The Liver and Alpha-1. Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION


Information for patients and the public and patient information about DNA / Biobanking across Europe

Big Data for Population Health and Personalised Medicine through EMR Linkages

a) Each facility shall have a medical record system that retrieves information regarding individual residents.

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

FINLAND ON A ROAD TOWARDS A MODERN LEGAL BIOBANKING INFRASTRUCTURE

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Maritime Super Income Protection Claim Form

Donating Life. The Workplace Partnership for Life Program

The Brain and Spine CenTer

Genetic Alliance BioBank: A Virtual Tour of Registry Solutions to Accelerate Research February 22, 2010

FastTest. You ve read the book now test yourself

CONSENT FORM TEMPLATE. Derivation and Distribution of Induced Pluripotent Stem (ips) Cell Lines Created from Donor Specimens

What you should know about Data Quality. A guide for health and social care staff

Fertility Facts and Figures 2008

Cord Blood Bank Business Plan

Ethical, Legal and Societal consideration in the design of Canadian Longitudinal Study on Aging (CLSA) Parminder Raina, Susan Kirkland and Christina

Taking Part in Research at University Hospitals Birmingham

EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases

CONTACT AND DEMOGRAPHIC INFORMATION (**Optional. For statistical purposes only) **Race Preferred Name **Are you a US military veteran?


EPIDEMIOLOGY OF HEPATITIS B IN IRELAND

Great-West G R O U P. Short Term Disability Income Benefits Employee s Statement

Medicine Safety Glossary

Blood Biobanking Chances and Risks. The Bavarian Red Cross Blood Donor Biobank

Checklist for personal accident, overseas student or foreign maid claim

Lung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD

Newborn Screening Issues

REQUEST FOR IMAGe SYNDROME TESTING

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Goodman Fielder Income Protection Claim Form

Breast Cancer s Link to Ovarian Cancer: It s in Your Genes. foundationforwomenscancer.org

Wayne Physical Medicine & Rehabilitation Associates 401 Hamburg Turnpike, Suite 105 Wayne, NJ 07470

N.E. WASHINGTON HEALTH PROGRAMS Notice of Privacy Practices Revised date: September 2013

1 ALPHA-1. The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) FOUNDATION FOUNDATION. A patient s guide to Alpha-1 liver disease

Appendix 6.2 Data Source Described in Detail Hospital Data Sets

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Educator s Guide to Sickle Cell Disease

Clinical Trials: Questions and Answers

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010

Reproductive Medicine Associates of New Jersey, LLC

X Linked Inheritance

Critical Illness Claim

Viral Hepatitis Case Report

Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.

MEASURING INEQUALITY BY HEALTH AND DISEASE CATEGORIES (USING DATA FROM ADMINISTRATIVE SOURCES)

A Greater Understanding. A Practical Guide to Clinical Trials

INTRODUCTION. Chapter One

Blood Transfusion. There are three types of blood cells: Red blood cells. White blood cells. Platelets.

Safe Blood Sampling Training Package

Guidelines for health professionals about DNA / Biobanking in Europe

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be

Medicare Supplement plan application

Your Cord Blood Donation Options

Leveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology. Presented by: Elisa Cascade, MediGuard/Quintiles

Understanding. Brain Tumors. Jana, diagnosed in 1999, with her husband, Paul.

ADVOCATE HEALTH CARE NOTICE OF PRIVACY PRACTICES

THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION.

Corporate Medical Policy Genetic Testing for Fanconi Anemia

GENETICS AND INSURANCE: QUANTIFYING THE IMPACT OF GENETIC INFORMATION

Preimplantation Genetic Diagnosis (PGD) in Western Australia

This fact sheet describes how genes affect our health when they follow a well understood pattern of genetic inheritance known as autosomal recessive.

REI Pearls: Pitfalls of Genetic Testing in Miscarriage

Sarasota Personal Medicine 1250 S. Tamiami Trail, Suite 202 Sarasota, FL Phone Fax

Elements for a Public Summary

NOTICE OF PRIVACY PRACTICES

Feasibility study to evaluate the usability of the newly developed health care management software ecare*seniors in primary care practices.

Array Comparative Genomic Hybridisation (CGH)

Joining SportsWareOnLine

The National Institute of Genomic Medicine (INMEGEN) was

Ethics and Patient Rights (EPR)

ARTICLE IN PRESS. Addictive Behaviors xx (2005) xxx xxx. Short communication. Decreased depression in marijuana users

Short-Term Disability Income Benefit. Employee s Statement

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED

Transcription:

Proposal of Common Data Elements for the European Platform of rare disease... Dear Colleague, this questionnaire focuses on a limited number of registry data elements, which are relevant either to link information from different rare disease patient registries and to perform a number of predefined analyses of interest to public health institutions, patients and their association, pharmaceutical industry and any other interested party which could financially support registries and the associated research activities. This questionnaire proposes definitions* and, as relevant, formats and permissible values of this select of data elements and asks about their feasibility in your registry. Answers are given mostly by ticking boxes in a same set of standard answers, so that your time dedicated to reply to the questionnaire will be kept to the minimum. Please complete your answer by 22 March 2013. We thank you for your kind collaboration. Domenica Taruscio, EPIRARE project coordinator Director of the National Centre for Rare Diseases www.iss.it/cnmr The EPIRARE project Coordinating Team www.epirare.eu *: for the sake of wider connectivity, proposed features take into consideration the data elements identified by the US Office for Rare Disease Research, initiatives undertaken by some EU Countries and other specialized research platforms.

Identification of the Registry * 1. Please, identify yourself Name of your Registry Respondent's name Respondent's e mail address 2. Which rare disease (or related group of rare disease) is in the scope of your Registry? One rare disease, please specify the disease's name: Related group of rare diseases, please specify the group's name: Other, please specify: 3. Please, indicate the Registry aims: (select all that apply) Epidemiology and Public Health Clinical research Treatment 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 If you have any comments: 5 6 4. Is your Registry part of a Network? Yes No 5. If YES, please indicate the Network: 5 6

On patient's personal data 6. Is your Registry able to collect the patient's National Social Security Code? Yes, the Registry is No,the Registry is not The Registry could be adapted to collect this information 7. Could your Registry collect the "First name of patient" defined as following: DEFINITION: "First name of patient as recorded in birth certificate, passport or identity card" FORMAT: full name, not initials 8. Could your Registry collect the "Last name of patient" defined as following: DEFINITION: "Last name of patient as recorded in birth certificate, passport or identity card" FORMAT: full name, not initials 9. Could your Registry collect the "Gender of patient" defined as following: DEFINITION: "Patient's physical sex at birth" PERMISSIBLE VALUES: male, female, other (in any format)

10. Could your Registry collect the "Patient's city of birth" defined as following: DEFINITION: "Name of city/town/village where the patient was born as it appears on the birth certificate, passport or identity card" FORMAT: full name of city

On patient's personal data 11. Could your Registry collect the "Patient's country of birth" defined as following: DEFINITION: "Name of country where the patient was born as it appears on the birth certificate, passport or identity card" FORMAT: full name of country 12. Could your Registry collect the "Patient's city of residence" defined as following: DEFINITION: "Name of city/town where the patient usually lives" FORMAT: full name of city 13. Could your Registry collect the "Patient's country of residence" defined as following: DEFINITION: "Name of country where the patient usually lives" FORMAT: full name of country

14. Could your Registry collect the "Date of patient's birth" defined as following: DEFINITION: "Date of patient's birth recorded in birth certificate, passport or identity card" FORMAT: complete date (year, month, day) in any format 15. Could your Registry collect the "Patient's date of death"? FORMAT: complete date (year, month, day) in any format This information is already collected This information could be adapted AND data already collected CAN be made compatible This information could be adapted, BUT data already collected CANNOT be made compatible This information cannot be adapted 16. Could your Registry collect "Patient's contact" defined as following: DEFINITION: "Any patient contact information, collected by the registry at the central or peripheral level, that allow to contact the patient"

On disease data 17. Please, indicate if your Registry collects data on: Patients with confirmed diagnosis only Both patients with confirmed and with suspected diagnosis 18. Is your Registry able to collect data on Genetic features of the rare disease? Yes, the Registry is No,the Registry is not The Registry could be adapted to collect data on Genetic features" 19. If Yes, please indicate what genetic data you collect:(select all that apply) Gene (HGNC Gene Symbol) Chromosome number Chromosomal reference sequence accession and version number RefSeqGene accession and version number Locus Reference Genomic (LRG) Variant description in HGVS format Variant description in other format Other Other, please specify 5 20. Could your Registry collect "Genetic features" on the patient's family members? 6 This information is already collected This information could be adapted AND data already collected CAN be made compatible This information could be adapted, BUT data already collected CANNOT be made compatible This information cannot be adapted

21. In case of disease subject to neonatal screening, could your Registry collect data on the "screening results" as following: DEFINITION: Results of laboratory screening test PERMISSIBLE VALUES: positive, negative, not tested, not known (in any format) 22. Could your Registry collect the "Clinical data of disease" defined as following: DEFINITION: "Any symptoms, clinical signs or surgery due to the patient's rare disease"

On disease data 23. Could your Registry collect the "Date of diagnosis" defined as following: DEFINITION: "Date when the rare disease diagnosis was confirmed" FORMAT: complete date (year, month, day) in any format 24. Could your Registry collect the "Date of disease onset" defined as following: DEFINITION: "Date when patient first began experiencing symptoms or signs of the rare disease" FORMAT: complete date (year, month, day) in any format 25. Could your Registry collect the "Date of first report to the Health Service" defined as following: DEFINITION: "Date when patient first reported symptoms or signs of the rare disease to physician" FORMAT: complete date (year, month, day) in any format

26. Could your Registry collect the "Co morbidity" defined as following: DEFINITION: "Other diseases observed in the patient" FORMAT: any format and coding system 27. Could your Registry collect the "Hospitalization" defined as following: DEFINITION: "Cumulative number of patient s admissions to the hospital due to the rare disease" FORMAT: number 28. Could your Registry collect data on Assistive devices" defined as following: DEFINITION: "Type of assistive devices used by patient" FORMAT: type of device

On data of disease 29. Is your Registry able to collect data on Patient's disability" caused by rare disease? Yes, the Registry is No,the Registry is not The Registry could be adapted to collect data on Patient's disability" 30. If your Registry is already collecting data on Patient's disability", please indicate what assessment questionnaire is used: 5 31. Is your Registry able to collect data on Patient's quality of life"? 6 Yes, the Registry is No,the Registry is not The Registry could be adapted to collect data on "Patient's quality of life" 32. If your Registry is already collecting data on Patient's quality of life", please indicate what assessment questionnaire is used: 5 33. Is your Registry able to collect the following data on "Centre which made diagnosis"? Yes No The Registry could be adapted to collect this data Full name of the Diagnosing Centre 6 City/Town where the Diagnosing Centre is Contact data of the the Diagnosing Centre 34. Is your Registry able to collect the following data on "Treating Centre"? Full name of the Treating Centre City/Town where the Treating Centre is Contact data of thetreating Centre Yes No The Registry could be adapted to collect this data

On treatments 35. Could your Registry collect data on Current orphan drug treatment" defined as following: DEFINITION: "A list of all current orphan drugs that a patient is currently taking" FORMAT: name of all active ingredient 36. Could your Registry collect data on Side effects of orphan drug treatments" defined as following: DEFINITION: "A list of confirmed or suspected side effects observed during the current orphan drug treatments" 37. Could your Registry collect data on Current drug treatment" defined as following: DEFINITION: "A list of all current drugs (different from orphan drugs) that a patient is currently taking" FORMAT: name of active ingredient

38. On which other types of treatment (different from medications) does your Registry collect data? (select all that apply) Cognitive Rehabilitation Physical Rehabilitation Surgery Other Other, please specify 5 6

On other data of the Registry 39. Is your Registry able to collect repeated observations to support longitudinal studies? Yes, The Registry is No, the Registry is not The Registry could be adapted to update its data 40. If YES, please indicate what data are updated: Yes No "Patient's city of residence" "Patient's country of residence" "Clinical data of disease" "Co morbidity" "Hospitalization" Assistive devices" "Patient's disability" Patient's quality of life" "Treating Centre" Current drug treatment" Current orphan drug treatment" Side effects of treatments" 41. Is your Registry able to collect the following data on "patient's recruitment" and biospecimen donation? Yes No The Registry could be adapted to collect this data Patient's willingness to be contacted to participate in a future trial Patient's willingness to be contacted about donating biological samples for research 42. If patient has already donated biological samples, could your Registry collect data on "Donation of biological samples"? This information is already collected This information could be adapted AND data already collected CAN be made compatible This information could be adapted, BUT data already collected CANNOT be made compatible This information cannot be adapted

43. If your Registry collects data on "Donation of biological samples", please indicate which data are collected: Yes No Type of biological sample (i.e. tissue or body fluid or other biospecimen) Name of the Biobank where the biological sample is stored up Contact details of Biobank where the biological sample is stored up, for communication purposes Other, please specify 5 6 44. Is your Registry able to collect data on "Transplantations"? Yes, The Registry is No, The Registry is not The Registry could be adapted to collect data on "Transplantations" 45. If YES, please indicate which data the Registry collects: Transplant material (i.e. organ or cells or other material) Yes No Date of transplantation